“During recent months, we also started important clinical trials advancing later-stage development programs, setting us up to potentially ... Announced that Sanofi acquired from Corxel ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

Just nine weeks after UnitedHealthcare CEO Brian Thompson was murdered on a weekday morning on a busy street, the luminaries ...

Sanofi said the GEMINI 1 and 2 trials of tolebrutinib in relapsing forms of MS are fully enrolled and should read out in time to meet its plan of filing for regulatory approval in the US in 2024.

Sanofi has won FDA approval for its sutimlimab for cold agglutinin disease (CAD) at the second time of asking, becoming the first approved therapy for the rare blood disorder in the US.

OMass Therapeutics appoints Birgitte Volck as Non-Executive DirectorOxford, United Kingdom – 26 February 2025 – OMass Therapeutics (‘OMass’ or ...

Boulder-based Enveda Biosciences, which uses machine learning to discover naturally occurring drug compounds, recently added ...

DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...

DelveInsight's High Potency Active Pharmaceutical Ingredients Market Insights report provides the current and forecast market ...